This page contains a Flash digital edition of a book.
NEWS


NHS Scotland could save £1m with Zeroderma emollients


The Zeroderma emollient range now offers more choice with four creams, one ointment, one gel and two bath additives - providing complete emollient therapy for moisturising, washing and bathing. Zeroderma products are similar in formulation to around 50% of currently prescribed emollients. Offering cost savings of up to 37%, many Health Boards and Clinical Commissioning Groups (CCGs) have adopted the Zeroderma range onto their formularies and cost savings are being made without compromising on patient care.


By changing from branded emollients to the cost effective Zeroderma emollient range, NHS Scotland could save £1 million a year. A Health Board who recently started using the Zeroderma range commented: ‘Emollient prescribing has been a useful area to address in terms of financial savings. Feedback from GPs has been positive, changes have been simple to implement and patient care has not been compromised.’


All Zeroderma products are sodium lauryl sulphate (SLS) free and are available on prescription.


To request samples for patient evaluation, email: zeroderma@thorntonross.com


www.trderma.co.uk


Thornton & Ross, Linthwaite, Huddersfield HD7 5QH. 01484 842217


UniDrug Distribution Group Rebrands to Alloga UK


UniDrug Distribution Group (UDG), one of the UK’s leading pharmaceutical pre-wholesale and contract logistics suppliers, has today been rebranded to Alloga UK. This follows the acquisition of full ownership of UDG by Alliance Boots, now Walgreens Boots Alliance, in August 2014.


Alloga is one of Europe’s leading specialist pre-wholesale and contract logistics providers, offering customers high quality, secure and robust services. It is part of the Pharmaceutical Wholesale Division of Walgreens Boots Alliance.


Throughout its 19-year history, UDG has run a successful business


and it will continue to focus on the growth and development of innovative services, under the Alloga UK brand.


Jeremy Main, Managing Director, Alliance Healthcare (Distribution) Limited, will oversee Alloga’s operations in the UK. He said: “The rebranding to Alloga UK marks an exciting step for the business and for our pharmaceutical customers. Being part of a shared brand will offer us new opportunities to further expand our pre-wholesale and contract logistics services, while increasing our brand recognition across Europe.”


Chris Williams, former Managing


Director of UDG, and new Managing Director of Alloga UK said: “Today we are changing our name to Alloga UK, but what will not change is our continued commitment to deliver excellent service and quality-focused solutions. We are excited about the opportunities this new venture will bring, and look forward to passing these benefits on to our valued manufacturing partners and their customers.”


UDG’s purple branding, on its vehicles and other marketing collateral, will be rebranded white and incorporate the Alloga logo. The new company name is Alloga UK Limited, trading as Alloga UK.


Meningitis B vaccine introduced in Scotland


All infants in Scotland are to be offered a vaccination against meningitis B through the NHS.


Scotland is now one of the few nations in the world to offer the vaccination which will prevent the life-threatening strain of meningitis to all infants.


The vaccine, called Bexsero, will be introduced to the immunisation programme for infants following negotiations on behalf of the Department of Health and the devolved government with manufacturer GlaxoSmithKline


Around 1,200 people, mainly babies and children, get meningitis caused by the meningococcal group B bacteria each year in the


44 - SCOTTISH PHARMACIST


UK, with around one in 10 dying from the infection.


The vaccination will be given in three doses at two, four and 12 months, with all babies in Scotland aged two months at the point of introduction being eligible. The Joint Committee on Vaccination and Immunisation (JCVI) has also advised that when the programme starts there should be a one-off, catch-up programme for babies aged three and four months of age.


Health Secretary Shona Robison said, “The Scottish Government has been consistent in its support for the introduction of the Meningitis B vaccine, Bexsero. We will now work to roll out the


vaccination programme as quickly as possible.


"The Meningitis B vaccine will now form part of the routine childhood immunisation programme in Scotland, underlining our commitment to ensuring the health and wellbeing of our children.


“Meningitis B is life-threatening and can affect people of any age, but is most common in babies and young children. By offering this vaccine as part of the routine programme we will be able prevent this and save lives. This disease can be devastating for children and their families and I’m very pleased we can now take the necessary steps to tackle its effects.”


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60